ANI Pharmaceuticals, Inc. logo ANIP - ANI Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 7
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $91.00 DETAILS
HIGH: $91.00
LOW: $91.00
MEDIAN: $91.00
CONSENSUS: $91.00
UPSIDE: 17.09%

Stock News

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement between the parties.

Jul 16, 2026 12:34 PM • globenewswire.com
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, a condition the company abbreviated as chronic NIU-PS.

Jul 13, 2026 08:55 AM • proactiveinvestors.com
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).

Jul 13, 2026 02:50 AM • globenewswire.com
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple

ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple

ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.

Jun 26, 2026 06:26 AM • seekingalpha.com

Price Targets